Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06087367
Other study ID # RC21_0456
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 20, 2021
Est. completion date March 24, 2025

Study information

Verified date October 2023
Source Nantes University Hospital
Contact Vincent Probst, PUPH
Phone 0240165279
Email vincent.probst@chu-nantes.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Cardiac channelopathies induce severe heart rhythm or conduction disorders. Mutations of the KCNH2 gene, that encodes the human (h) ERG channel, is responsible for 30-40% of all cases of long QT syndrome (inherited LQT2). Besides, hERG is frequently responsible for off-target effects of several pharmacological agents (acquired LQT2). With the advent of Next Generation Sequencing, hundreds of new KCNH2 variants are accumulating in regional databases including those developed by french centers of references. Worldwide, we estimate there are more than 1000 variants for hERG channel. Unfortunately, many of these new variants appear to be of unknown functional significance in spite of available clinical and genetic information. Little is known on whether they affect the channel biophysical properties, its expression at the cell surface and/or its structure. Yet, this information is crucial to determine the real degree of pathogenicity of these variants, and therefore to make the proper diagnosis on inherited LQT2, counsel the patient for his treatment and improve the management of the patient's life. Our ambition is therefore to tackle this issue of variant significance by (i) launching a large-scale multi-functional evaluation of hERG variants, (ii) introducing for the first time a formatted large-scale pathogenicity annotation score for all variants that have been functionally evaluated by this multi-parametric approach, and (iii) regrouping all the relevant information collected in every French Regional centers of reference into a single National database hosted by an infrastructure that possesses enough flexibility for continuous data implementation and cross-referencing. The database will integrate the latest International guidelines for functional pathogenicity annotation. This project will also include the pharmacological characterization of several drugs susceptible to produce acquired LQT2 with variable severities. We aim to understand whether there are structural regions within hERG channel in which the introduction of a variant is more prone to increase the risk of acquired LQT2 or if, on the contrary, a set of variants may relatively protect some patients against LQT2-inducing drugs.


Recruitment information / eligibility

Status Recruiting
Enrollment 600
Est. completion date March 24, 2025
Est. primary completion date March 24, 2025
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patients carrier of a mutation in KCNH2 gene Exclusion Criteria: - Patients who refuse to take part to research

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Nantes university hospital Nantes Loire-atlantique
France Hôpital Bichat - Claude Bernard Paris

Sponsors (3)

Lead Sponsor Collaborator
Nantes University Hospital Centre National de la Recherche Scientifique, France, Institut National de la Santé Et de la Recherche Médicale, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary To develop a database listing KCNH2 variants and their clinical impact Biophysical and pharmacological characterization; Trafficking impact of hERG variants; Structural impact of hERG variants using modeling tools 42 months
Secondary To stratify KCNH2 gene variants according to their sensitivity to drugs Stratify KCNH2 gene variants according to their sensitivity to drugs known to induce acquired type 2 long QT syndrome 42 months
See also
  Status Clinical Trial Phase
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4
Completed NCT01648205 - Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients Phase 2
Recruiting NCT04675788 - Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening Phase 4
Completed NCT05759962 - Phase 1 Study of LQT-1213 in Healthy Adults Phase 1
Enrolling by invitation NCT05903313 - A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
Terminated NCT02439645 - A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes
Recruiting NCT00221832 - Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases N/A
Completed NCT04706104 - QT Measurement Techniques and Anesthesia Management
Recruiting NCT04336644 - Continuous Versus Intermittent cARdiac Electrical moNitorinG N/A
Recruiting NCT02814981 - Hydroxyzine and Risk of Prolongation of QT Interval N/A
Completed NCT02876380 - Prospective Identification of Long QT Syndrome in Fetal Life
Completed NCT02425189 - The Canadian National Long QT Syndrome Registry
Completed NCT00399412 - ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients N/A
Completed NCT02513940 - Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes Phase 4
Completed NCT03182777 - Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies N/A
Completed NCT02441829 - Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function Phase 1
Completed NCT01849003 - Study of the Effect of GS-6615 in Subjects With LQT-3 Phase 1
Completed NCT00316459 - Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects Phase 1
Completed NCT00292032 - Registry of Unexplained Cardiac Arrest
Recruiting NCT05348564 - Comparing Direct vs Indirect Methods for Cascade Screening N/A